Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, ...

Recursion Pharmaceuticals (RXRX) shares recently closed at US$3.98, with the stock showing a negative return over the past month and past 3 months, which may prompt investors to reassess its current ...

Following the transaction, Borgeson directly owns 6,429,863 shares of Recursion Pharmaceuticals. The company, while holding more cash than debt with a current ratio of 4.6, is quickly burning through ...

Additionally, Recursion Pharmaceuticals plans to present updated clinical data from the TUPELO trial in a webinar scheduled for December 8, 2025. The webinar will provide more insights into the safety ...